The Latest in FDA Evaluations and Research

FDA News

Related Topics: FDA News

News Feed Item

The Zacks Analyst Blog Highlights: United Therapeutics, Repros Therapeutics, Amgen, Regeneron and Aegerion

CHICAGO, Sept. 4, 2014 /PRNewswire/ -- announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the United Therapeutics (Nasdaq:UTHR-Free Report), Repros Therapeutics (Nasdaq:RPRX-Free Report), Amgen (Nasdaq:AMGN-Free Report), Regeneron (Nasdaq:REGN-Free Report) and Aegerion (Nasdaq:AEGR-Free Report).

Zacks Investment Research, Inc.,

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

Here are highlights from Wednesday's Analyst Blog:

Biotech Stock Roundup

Highlights in the biotech sector last week include a favorable court ruling for United Therapeutics' (Nasdaq:UTHR-Free Report) in a patent infringement case, positive late-stage data on Repros Therapeutics' (Nasdaq:RPRX-Free Report) testosterone replacement treatment and the filing of the first Biologics License Application (BLA) for a PCSK9 inhibitor.

Recap of the Week's Most Important Stories

1. United Therapeutics scored a huge win in its patent infringement lawsuit against Sandoz regarding Remodulin. The favorable ruling has removed a significant overhang on the shares, which were up 28.5% on the news (Read more: United Therapeutics Soars on Remodulin Patent Case Win). The company touched a new 52-week high early this week.

2. It was an eventful week on the pipeline front for Amgen (Nasdaq:AMGN-Free Report). The company said that its chronic heart failure drug, ivabradine, will be reviewed on a priority basis by the FDA (Read more: Amgen's Chronic Heart Failure Drug Gets Priority Review). Amgen also submitted its PCSK9 inhibitor, evolocumab, for FDA approval. Evolocumab is one of the most important candidates in Amgen's pipeline and represents huge commercial potential, once approved and launched.

Although Amgen's regulatory application is the first to be filed in the U.S., Sanofi and Regeneron (Nasdaq:REGN-Free Report) are not far behind with their PCSK9 inhibitor which is expected to be filed by year end (Read more: Amgen Submits Regulatory Application for PCSK9 Inhibitor).

3. Repros' shares surged 18.5% with the company reporting positive late-stage data on its key pipeline candidate, Androxal. The testosterone replacement treatment was found to be superior to a currently approved product. Repros expects to file for approval in the U.S. by year end (Read more:Repros Reports Encouraging Late-Stage Data on Androxal).

4. Aegerion (Nasdaq:AEGR-Free Report) shares were up 5.1% on news that the FDA's warning letter regarding certain statements made regarding cholesterol drug, Juxtapid, has been resolved (Read more: Aegerion Resolves FDA's Warning on Juxtapid, Lifts Overhang).

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today.

About Zacks is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros.  In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.

Get the full Report on UTHR - FREE

Get the full Report on RPRX - FREE

Get the full Report on AMGN - FREE

Get the full Report on REGN - FREE

Get the full Report on AEGR - FREE

Follow us on Twitter:

Join us on Facebook:

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

[email protected]

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release.

Logo -

SOURCE Zacks Investment Research, Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.